Suparada Khanaruksombat

ORCID: 0000-0002-5577-2660
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Drug-Induced Adverse Reactions
  • Contact Dermatitis and Allergies
  • Urticaria and Related Conditions
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Peptidase Inhibition and Analysis
  • Cancer Immunotherapy and Biomarkers
  • Food Allergy and Anaphylaxis Research
  • Protein Hydrolysis and Bioactive Peptides
  • Aquaculture Nutrition and Growth
  • Aquatic life and conservation
  • Studies on Chitinases and Chitosanases
  • Fish Biology and Ecology Studies

Siriraj Hospital
2024

Mahidol University
2024

Chulalongkorn University
2024

Kasetsart University
2014

Background: Immune evasion in cancer is a multifaceted process that synchronizes pro-tumoral immune infiltration, immunosuppressive inflammation, and inhibitory checkpoint expression (IC). Recent developments have immunotherapies such as blockade (ICB) chimeric antigen receptor T-cell (CAR-T) therapy effectively impede this but benefit limited patient cohort. This investigation introduces systemic immunotherapeutic strategy by inhibition of master-regulators (MR-IE). Methods: We utilized the...

10.20944/preprints202410.1274.v1 preprint EN 2024-10-16

ABSTRACT Drug reactions with eosinophilia and systemic symptoms (DRESS) Stevens‐Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse hypersensitivity distinct clinical manifestations. Regulatory T (Treg) cells may behave differently in these syndromes, contributing to their diverse features outcomes. This study compared Treg dynamics between DRESS SJS/TEN patients during the acute recovery phases. Flow cytometry quantitatively analysed defined immunophenotype of...

10.1111/exd.70007 article EN Experimental Dermatology 2024-11-01

Background: Cancer immune evasion is a multifaceted process that synchronizes pro-tumoral infiltration, immunosuppressive inflammation, and inhibitory checkpoint expression (IC). Current immunotherapies combat this issue by reinstating immunosurveillance of tumors; however, it benefits limited patient population. Thus, more effective immunotherapeutic strategy warranted to cater specific populations. This investigation introduces novel via inhibition master regulators (MR-IE). Methods:...

10.3390/cancers16244197 article EN Cancers 2024-12-17
Coming Soon ...